Effect of B-Vitamin Therapy on Progression of Diabetic Nephropathy A Randomized Controlled Trial

被引:219
作者
House, Andrew A. [2 ]
Eliasziw, Misha [4 ]
Cattran, Daniel C. [5 ]
Churchill, David N. [6 ]
Oliver, Matthew J. [5 ]
Fine, Adrian [7 ]
Dresser, George K. [3 ]
Spence, J. David [1 ,3 ]
机构
[1] Univ Western Ontario, Robarts Res Inst, Stroke Prevent & Atherosclerosis Res Ctr, London, ON N6G 2V2, Canada
[2] Univ Western Ontario, Div Nephrol, London, ON N6G 2V2, Canada
[3] Univ Western Ontario, Div Clin Pharmacol, London, ON N6G 2V2, Canada
[4] Univ Calgary, Dept Community Hlth Sci Clin Neurosci & Oncol, Calgary, AB, Canada
[5] Univ Toronto, Div Nephrol, Toronto, ON, Canada
[6] McMaster Univ, Div Nephrol, Hamilton, ON, Canada
[7] Univ Manitoba, Div Nephrol, Winnipeg, MB, Canada
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2010年 / 303卷 / 16期
基金
加拿大健康研究院;
关键词
CARDIOVASCULAR EVENTS; FOLIC-ACID; RISK-FACTOR; HOMOCYSTEINE; MORTALITY; HYPERHOMOCYSTEINEMIA; CREATININE; INTERVENTION; PREDICTION; DISEASE;
D O I
10.1001/jama.2010.490
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Hyperhomocysteinemia is frequently observed in patients with diabetic nephropathy. B-vitamin therapy (folic acid, vitamin B-6, and vitamin B-12) has been shown to lower the plasma concentration of homocysteine. Objective To determine whether B-vitamin therapy can slow progression of diabetic nephropathy and prevent vascular complications. Design, Setting, and Participants A multicenter, randomized, double-blind, placebo-controlled trial (Diabetic Intervention with Vitamins to Improve Nephropathy [DIVINe]) at 5 university medical centers in Canada conducted between May 2001 and July 2007 of 238 participants who had type 1 or 2 diabetes and a clinical diagnosis of diabetic nephropathy. Intervention Single tablet of B vitamins containing folic acid (2.5 mg/d), vitamin B-6 (25 mg/d), and vitamin B-12 (1 mg/d), or matching placebo. Main Outcome Measures Change in radionuclide glomerular filtration rate (GFR) between baseline and 36 months. Secondary outcomes were dialysis and a composite of myocardial infarction, stroke, revascularization, and all-cause mortality. Plasma total homocysteine was also measured. Results The mean (SD) follow-up during the trial was 31.9 (14.4) months. At 36 months, radionuclide GFR decreased by a mean (SE) of 16.5 (1.7) mL/min/1.73 m(2) in the B-vitamin group compared with 10.7 (1.7) mL/min/1.73 m(2) in the placebo group (mean difference, -5.8; 95% confidence interval [CI], -10.6 to -1.1; P=.02). There was no difference in requirement of dialysis (hazard ratio [HR], 1.1; 95% CI, 0.4-2.6; P=.88). The composite outcome occurred more often in the B-vitamin group (HR, 2.0; 95% CI, 1.0-4.0; P=.04). Plasma total homocysteine decreased by a mean (SE) of 2.2 (0.4) mu mol/L at 36 months in the B-vitamin group compared with a mean (SE) increase of 2.6 (0.4) mu mol/L in the placebo group (mean difference, -4.8; 95% CI, -6.1 to -3.7; P<.001, in favor of B vitamins). Conclusion Among patients with diabetic nephropathy, high doses of B vitamins compared with placebo resulted in a greater decrease in GFR and an increase in vascular events.
引用
收藏
页码:1603 / 1609
页数:7
相关论文
共 35 条
[1]   Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease - A randomized trial [J].
Albert, Christine M. ;
Cook, Nancy R. ;
Gaziano, J. Michael ;
Zaharris, Elaine ;
MacFadyen, Jean ;
Danielson, Eleanor ;
Buring, Julie E. ;
Manson, JoAnn E. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (17) :2027-2036
[2]  
Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO
[3]  
2-I
[4]   Epidemiology of Homocysteine as a Risk Factor in Diabetes [J].
Becker, A. ;
Smulders, Y. M. ;
van Guldener, C. ;
Stehouwer, C. D. A. .
METABOLIC SYNDROME AND RELATED DISORDERS, 2003, 1 (02) :105-120
[5]   Homocysteine lowering and cardiovascular events after acute myocardial infarction [J].
Bonaa, KH ;
Njolstad, I ;
Ueland, PM ;
Schirmer, H ;
Tverdal, A ;
Steigen, T ;
Wang, H ;
Nordrehaug, JE ;
Arnesen, E ;
Rasmussen, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (15) :1578-1588
[6]   Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women [J].
Bostom, AG ;
Silbershatz, H ;
Rosenberg, IH ;
Selhub, J ;
D'Agostino, RB ;
Wolf, PA ;
Jacques, PF ;
Wilson, PWF .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (10) :1077-1080
[7]   Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia - An effect reversible with vitamin C therapy [J].
Chambers, JC ;
McGregor, A ;
Jean-Marie, J ;
Obeid, OA ;
Kooner, JS .
CIRCULATION, 1999, 99 (09) :1156-1160
[8]   Improved vascular endothelial function after oral B vitamins - An effect mediated through reduced concentrations of free plasma homocysteine [J].
Chambers, JC ;
Ueland, PM ;
Obeid, OA ;
Wrigley, J ;
Refsum, H ;
Kooner, JS .
CIRCULATION, 2000, 102 (20) :2479-2483
[9]   The burden of diabetes and its complications: Trends and implications for intervention [J].
Chaturvedi, Nish .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 :S3-S12
[10]   Homocysteine and risk of ischemic heart disease and stroke -: A meta-analysis [J].
Clarke, R ;
Collins, R ;
Lewington, S ;
Donald, A ;
Alfthan, G ;
Tuomilehto, J ;
Arnesen, E ;
Bonaa, K ;
Blacher, J ;
Boers, GHJ ;
Bostom, A ;
Bots, ML ;
Grobee, DE ;
Brattström, L ;
Breteler, MMB ;
Hofman, A ;
Chambers, JC ;
Kooner, JS ;
Coull, BM ;
Evans, RW ;
Kuller, LH ;
Evers, S ;
Folsom, AR ;
Freyburger, G ;
Parrot, F ;
Genst, J ;
Dalery, K ;
Graham, IM ;
Daly, L ;
Hoogeveen, EK ;
Kostense, PJ ;
Stehouwer, CDA ;
Hopknis, PN ;
Jacques, P ;
Selhub, J ;
Luft, FC ;
Jungers, P ;
Lindgren, A ;
Lolin, YI ;
Loehrer, F ;
Fowler, B ;
Mansoor, MA ;
Malinow, MR ;
Ducimetiere, P ;
Nygard, O ;
Refsum, H ;
Vollset, SE ;
Ueland, PM ;
Omenn, GS ;
Beresford, SAA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (16) :2015-2022